Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer

Cancer Research

Volumn 68, Issue 20, 2008, Pages 8400-8409

  Park, Kyong Hwa ^a   Gad, Ekram ^b   Goodell, Vivian ^b   Dang, Yushe ^b   Wild, Thayer ^b   Higgins, Doreen ^b   Fintak, Patty ^b   Childs, Jennifer ^b   Dela Rosa, Corazon ^b   Disis, Mary L ^b  

^a Korea University   (South Korea)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; SOMATOMEDIN BINDING PROTEIN 2;

ADOPTIVE TRANSFER; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SEQUENCE HOMOLOGY; T LYMPHOCYTE; TUMOR IMMUNITY;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTERFERON TYPE II; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 54249086700     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5891     Document Type: Article

References (48)

1. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
2. Day RS, Shackney SE, Peters WP. The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer. Br J Cancer 2005;92:47-54.
3. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
4. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005;23:7536-45.
5. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007;67:1842-52.
6. Salazar LG, Knutson KL, Dang Y, Dela Rosa C, Disis ML. Long-term immunity after immunization with a HER-2/neu vaccine [abstract]. Proc Amer Assoc Cancer Res 2004;45:1414.
7. Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 2005;65:650-6.
8. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007;6:115-20.
9. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
10. Busund LT, Richardsen E, Busund R, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005;58:361-6.
11. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007;104:5563-8.
12. Martin JL, Baxter RC. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 2007;148:2532-41.
13. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007;26:5966-72.
14. Disis ML, dela Rosa C, Goodell V, et al. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 2006;308:13-8.
15. Goodell V, McNeel D, Disis ML. His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 2008;9:23.
16. Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9:5559-65.
17. Lu J, Celis E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 2000;60:5223-7.
18. Bui HH, Sidney J, Peters B, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005;57:304-14.
19. Dang Y, Knutson KL, Goodell V, et al. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 2007;13:1883-91.
20. Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol 2004;135:322-9.
21. Knutson KL, Lu H, Stone B, et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006;177:1526-33.
22. Goodell V, Disis ML. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 2005;299:129-38.
23. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
24. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004;10:1796-806.
25. Yu H, Nicar MR, Shi R, et al. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001;57:471-5.
26. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-50.
27. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004;32:859-68.
28. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36.
29. + T-cell immune response. Int J Cancer 2004;109:909-18.
30. + T cell responses against NYESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003;100:8862-7.
31. Jager D, Taverna C, Zippelius A, Knuth A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 2004;53:144-7.
32. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
33. Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol 2007;32:111-8.
34. Uemura Y, Senju S, Maenaka K, et al. Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for glutamic acid decarboxylase 65-specific TCRs. J Immunol 2003;170:947-60.
35. Croxford JL, Olson JK, Anger HA, Miller SD. Initiation and exacerbation of autoimmune demyelination of the central nervous system via virus-induced molecular mimicry: implications for the pathogenesis of multiple sclerosis. J Virol 2005;79:8581-90.
36. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996;184:647-57.
37. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
38. Menard S, Aiello P, Tagliabue E, et al. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res 2000;60:273-5.
39. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006;177:84-91.
40. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80.
41. Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 2006;59:972-7.
42. Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res 2006;66:9754-61.
43. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000;20:17-56.
44. + T cell reactivity to a model tumor antigen. J Immunol 2000;164:562-5.
45. + T cell-dependent tumor eradication in vivo. J Immunol 2000;165:5495-501.
46. Giuntoli RL 2nd, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002;8:922-31.
47. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon γ. Curr Opin Immunol 1999;11:76-81.
48. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci U S A 2003;100:10902-6.